journal article·2022-06Open access

DNA aptamer S11e recognizes fibrosarcoma and acts as a tumor suppressor

Yunyi Liu, Cheng Peng, Hui Zhang, Juan Li, Hailong Ou, Yang Sun, Chaoqi Wen, Dan Qi, Xiaoxiao Hu, Erxi Wu, Weihong Tan

Abstract

Fibrosarcoma is a serious malignant mesenchymal tumor with strong invasiveness, high recurrence, and poor prognosis. Currently, surgical resection is the main treatment for fibrosarcoma. However, due to the lack of specific biomarkers, the inability to accurately diagnose fibrosarcoma can lead to sub-optimal surgical outcomes and decreased survival. Here, we seek to address this translational barrier and we show that DNA aptamer S11e was able to recognize fibrosarcoma cells (HT1080) but not human embryonic lung fibroblast cells with Kd values in the nanomolar range. In addition, we found that S11e discerned tumors in HT1080 xenograft mouse models and tumor tissues from fibrosarcoma patients. Furthermore, we demonstrated that S11e internalized into HT1080 cells independent of the lysosome pathway and located in mitochondria. Moreover, we revealed that S11e promoted the apoptosis of HT1080 cells and inhibited HT1080 cell migration. Finally, we investigated the biologically functional cellular target of S11e using a mass spectrometry approach, and identified that Diablo/SMAC protein is a cellular binding protein of S11e, by interacting to which S11e inhibited HT1080 cell migration and invasion. Taken together, these results provide the evidence that S11e may be useful for early diagnosis, targeted therapy, and prognostication of fibrosarcoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA modifications and cancer · RNA Research and Splicing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (33)

Show source-provided references
1. World Health Organization classification of bone and soft tissue tumors: modifications and implications for radiologists10.1055/s-2008-1038310 ↗
2. Comparative proteomic analysis of fibrosarcoma and skin fibroblast cell lines10.1007/s13277-014-2672-8 ↗
3. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases10.1002/ijc.22239 ↗
4. Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies10.18632/oncotarget.20136 ↗
5. Aptamers: active targeting ligands for cancer diagnosis and therapy10.7150/thno.10257 ↗
6. Systematic evaluation of cell-SELEX enriched aptamers binding to breast cancer cells10.1016/j.biochi.2017.10.007 ↗
7. Rapid and label-free strategy to isolate aptamers for metal ions10.1021/acsnano.6b02558 ↗
8. An efficient RNA aptamer against human influenza B virus hemagglutinin10.1093/jb/mvj095 ↗
9. Molecular self-assembly of bioorthogonal aptamer-prodrug conjugate micelles for hydrogen peroxide and pH-independent cancer chemodynamic therapy10.1021/jacs.9b10755 ↗
10. Chemo-drug controlled-release strategies of nanocarrier in the development of cancer therapeutics
11. A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration10.1016/j.ophtha.2015.09.004 ↗
12. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation10.1021/nn507494p ↗
13. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma10.1007/s10637-013-0045-6 ↗
14. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys10.1182/blood-2012-09-456756 ↗
15. Update on current and future novel therapies for dry age-related macular degeneration10.1586/17512433.2013.829645 ↗
16. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease10.1160/TH10-01-0027 ↗
17. Aptamer therapeutics in cancer: current and future10.3390/cancers10030080 ↗
18. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization10.1182/blood-2013-03-493924 ↗
19. Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer10.1093/nar/gky990 ↗
20. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease10.1038/nrd1955 ↗
21. Nucleolin on the cell surface as a new molecular target for gastric cancer treatment10.1248/bpb.33.796 ↗
22. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells10.1158/0008-5472.CAN-07-5723 ↗
23. Physicochemical stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications10.1093/nass/nrn031 ↗
24. Cell death regulation by the mammalian IAP antagonist Diablo/Smac10.1023/A:1014318615955 ↗
25. Molecular recognition and in-vitro-targeted inhibition of renal cell carcinoma using a DNA aptamer10.1016/j.omtn.2018.07.015 ↗
26. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells10.1039/b904476k ↗
27. Locked nucleic acid and aptamers10.1089/nat.2012.0382 ↗
28. Identification and application of an aptamer targeting papillary thyroid carcinoma using tissue-SELEX10.1021/acs.analchem.9b01000 ↗
29. Targeting mitochondria for cancer therapy10.1038/nrd3137 ↗
30. Mitochondria: dynamic organelles in disease, aging, and development10.1016/j.cell.2006.06.010 ↗
31. Betanodavirus up-regulates chaperone GRP78 via ER stress: roles of GRP78 in viral replication and host mitochondria-mediated cell death10.1007/s10495-010-0565-x ↗
32. Apoptosis is regulated by the VDAC1 N-terminal region and by VDAC oligomerization: release of cytochrome c, AIF and Smac/Diablo10.1016/j.bbabio.2010.03.003 ↗
33. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands10.1161/01.HYP.0000035522.63647.D3 ↗